Thomson et al. suggested that the sensitivity to inhibition of EGFR depends on the degree of EMT occurrence in EGFR-expressing human non-small cell lung cancer (NSCLC) xenograft (Thomson et al. 2005). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.